ArticleFrontiers in oncology2025
Downregulation of HDGF inhibits tumorigenic phenotypes of hypopharyngeal squamous cell carcinoma by suppressing the AKT/mTOR/VEGF pathway.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypopharyngeal squamous cell carcinoma (HSCC), an aggressive HNSCC subtype characterized by high metastatic potential and poor prognosis, frequently overexpresses hepatoma-derived growth factor (HDGF), a factor implicated in tumor progression. This study investigates the functional role of HDGF in HSCC and its regulatory mechanisms involving epithelial-mesenchymal transition (EMT) and the AKT/mTOR/VEGF signaling pathway. Methods: Bioinformatic analysis of TCGA data revealed elevated HDGF expression in HSCC tissues, significantly correlating with clinical stage. HDGF expression was depleted in the FaDu HSCC cell line using siRNA. Cell proliferation, migration, and invasion were assessed using CCK-8, wound healing, and Transwell assays, respectively. Western blotting evaluated changes in EMT markers (E-cadherin, N-cadherin, Snail, Slug) and key components of the AKT/mTOR/VEGF pathway (p-AKT, p-mTOR, VEGFA). Results: Bioinformatics analysis confirmed HDGF overexpression across HNSCC subtypes. In FaDu HSCC cells, siRNA-mediated HDGF knockdown significantly attenuated proliferation, migration, and invasion. Mechanistically, HDGF depletion reversed EMT progression, evidenced by E-cadherin upregulation and concurrent N-cadherin, Snail, and Slug downregulation. Western blotting demonstrated that HDGF knockdown suppressed AKT/mTOR signaling, as indicated by reduced p-AKT and p-mTOR levels, and decreased VEGFA expression. Conclusion: Our findings establish HDGF as a key promoter of HSCC progression through dual regulation of EMT and AKT/mTOR/VEGF pathways, suggesting its potential as a therapeutic target. These results provide mechanistic insights for developing HDGF-targeted strategies against this lethal malignancy, warranting further clinical exploration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.